Company Profile
MacroGenics Stock Price, News & Analysis
- Ticker:
- MGNX
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
4.00 USD (+8.11%)
Close
Last updated: July 27, 2026
257M USD
Market cap
Why the stock is moving
As of Jul 27, 2026, MGNX closed up 8.11% at $4.00. No new same-company headline was identified in the current news window.
Company overview
Business overview
MacroGenics is an oncology company focused on engineered antibodies and targeted cancer therapies. The company has long been known for antibody engineering and immuno-oncology programs.
Geographic Base and Sector Classification
Headquartered in the United States and listed on NASDAQ, MacroGenics sits in specialty oncology biotechnology.
Business Model Characteristics
Its model depends on clinical data, partner economics, and the ability to create differentiated antibody assets.
Position Within the Biotechnology Landscape
MacroGenics is a classic antibody oncology name whose valuation remains highly data-driven.
Future catalysts
MacroGenics’ next three months are about its antibody and bispecific pipeline, especially whether the company can keep advancing programs that still have partnering or development value. Investors will watch for any data that show the platform can still produce differentiated oncology assets.
Recent news
The five most recent related feed items are shown below in reverse chronological order.
- 01
GSK to establish new flagship R&D centre on Cambridge Biomedical Campus, UK
GSK · Source: GSK plc
- 02
Legend Biotech to Host Investor Conference Call on Second Quarter 2026 Results
LEGN · Source: Legend Biotech Corporation
- 03
- 04
- 05
Kymera Therapeutics Appoints Terence Rooney, MD, as Chief Medical Officer
KYMR · Source: Kymera
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of MacroGenics (MGNX)?
MacroGenics (MGNX) most recently closed at 4.00 USD, a +8.11% move versus the previous session.
What is the market cap of MacroGenics (MGNX)?
MacroGenics currently has a market capitalization of 257M USD on BioPharmSignal.
What does MacroGenics do?
MacroGenics is an oncology company focused on engineered antibodies and targeted cancer therapies. The company has long been known for antibody engineering and immuno-oncology programs.
On which exchange is MGNX stock listed?
MacroGenics (MGNX) is associated with NASDAQ, United States, Biopharma.
What is MacroGenics?
MacroGenics’ next three months are about its antibody and bispecific pipeline, especially whether the company can keep advancing programs that still have partnering or development value.
Which conditions is MacroGenics targeting with MacroGenics?
MacroGenics is associated with oncology, cancer therapeutics based on its company overview and current catalyst commentary.
How does MacroGenics describe recent progress with MacroGenics?
MacroGenics’ next three months are about its antibody and bispecific pipeline, especially whether the company can keep advancing programs that still have partnering or development value.
What is Investors?
Investors will watch for any data that show the platform can still produce differentiated oncology assets.